Long-term Endeavor data buoy Medtronic's market penetration hopes
This article was originally published in Clinica
Executive Summary
In what looks set to boost market penetration prospects for Medtronic's first commercial drug-eluting stent (DES), the firm has released positive long-term trial data for its ABT-578-loaded Endeavor product, which was launched outside the US only a few weeks ago, writes Neena Brizmohun from the European Society of Cardiology meeting in Stockholm, Sweden.